Compare XGN & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XGN | STIM |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.7M | 120.4M |
| IPO Year | 2014 | 2018 |
| Metric | XGN | STIM |
|---|---|---|
| Price | $8.46 | $2.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $10.14 | $5.75 |
| AVG Volume (30 Days) | 273.4K | ★ 1.1M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.25 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $52,776,000.00 |
| Revenue This Year | $11.02 | $8.63 |
| Revenue Next Year | $10.28 | $9.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.59 | $0.80 |
| 52 Week High | $12.23 | $3.44 |
| Indicator | XGN | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 29.28 |
| Support Level | $7.81 | $1.99 |
| Resistance Level | $8.89 | $2.13 |
| Average True Range (ATR) | 0.42 | 0.13 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 58.33 | 2.31 |
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.